C oronary artery disease is a progressive disease with high morbidity and mortality rates in the United States. After myocardial infarction (MI), the limited ability of the surviving cardiac cells to proliferate renders the damaged heart susceptible to unfavorable remodeling processes and morbid sequelae such as heart failure. Current therapies for patients who have coronary artery disease or MI include lifestyle modification, drug treatments, percutaneous coronary intervention, bypass surgery, and orthotopic heart transplantation. In recent years, stem cell therapy has provided a promising means of replacing cardiomyocytes lost during MI through induction of endogenous regenerative processes and transferring of progenitor cells to new myocardium. 1 Several types of stem cells have been shown to have a beneficial effect in small animal models, including bone marrow mononuclear cells, 2 mesenchymal stem cells, 3 endothelial progenitor cells, 4 and human embryonic stem cell-derived cardiomyocytes, 5 to name a few. However, large placebo-controlled clinical trials have not shown a consistent benefit in using stem cells to treat patients with ischemic heart disease. 6 In recent years, a number of studies have confirmed the presence of resident "progenitor cells" in the myocardium. 1 These cells can be isolated and expanded ex vivo and can also differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells under the appropriate culturing conditions. However, the low survival of the transplanted stem cells, including cardiac progenitor cells (CPCs), in the infarcted myocardium is a major obstacle to achieving long-term improvements after stem cell therapy. [7] [8] [9] [10] [11] [12] [13] Therefore, developing novel prosurvival strategies to boost stem cell survival will be highly beneficial to this field.
MicroRNAs (miRNAs) are short 20 to 22-nucleotide RNA molecules that are expressed in a tissue-specific and developmentally regulated manner. MiRNAs mainly function as negative regulators of gene expression in a variety of organisms, through binding with imperfect complementarity to the 3ЈUTR of their target mRNAs. 14 In the heart, a large number of miRNAs are expressed and are considered to be important regulators in cardiac development and pathophysiology. 14 In addition, recent studies indicate that miRNAs can be used as therapeutic targets for various cardiovascular diseases. [15] [16] [17] In this study, we hypothesize that miRNAs may play a significant role in regulating survival and apoptosis of CPCs and in improving engraftment posttransplantation. We demonstrate for the first time that CPCs treated with a miRNA prosurvival cocktail can significantly improve cell engraftment and functional recovery in a murine model of MI.
Methods

Isolation and Maintenance of Sca-1 ؉ CPCs
Heart tissue explants are isolated from transgenic mice with ubiquitin promoter constitutively driving firefly luciferase (Fluc) and green fluorescent protein. The minced heart pieces are subjected to enzyme dissociation with 0.2% trypsin and 0.1% collagenase IV (Worthington Biochemical, Lakewood, NJ) in phosphate-buffered saline 3 times for 5 minutes at 37°C. Afterward, the remaining tissue fragments were cultured in the CPC medium (Iscove Modified Dulbecco IMDM with 15% fetal calf serum, 100 U/mL penicillin G, 100 g/mL streptomycin, 2 mmol/L L-glutamine, and 0.1 mmoL/L 2-mercaptoethanol) at 37°C. After approximately 2 weeks, we harvested small, phase-bright cells formed from adherent explants by washing with D-Hanks solution. We then enrich the Sca-1 ϩ cells with anti-Sca-1 microbeads (Miltenyi Biotec) as previously described. 18 The enriched Sca-1 ϩ cells were seeded on gelatin coated dishes in CPC medium as described above.
In Vitro Differentiation of CPCs
For cardiac and smooth muscle differentiation, CPCs were cultured in poly-D-lysine-coated plates in differentiation medium containing 35% Iscove modified Dulbecco medium with 10% fetal bovine serum/65% Dulbecco modified Eagle medium-Ham F-12 mix containing 2% B27, 0.1 mmol/L 2-mercaptoethanol, 10 ng/mL epidermal growth factor (R&D Systems, Minneapolis, MN), 20 ng/mL basic fibroblast growth factor, 40 nmol/L cardiotrophin-1, 40 nmol/L thrombin (Sigma-Aldrich, St Louis, MO), 100 U/mL penicillin G, 100 g/mL streptomycin, and 2 mmol/L glutamine. For endothelial differentiation, CPCs were cultured on fibronectin-coated plates with EGM-2 medium (Lonza) with an extra 20 ng/mL of vascular endothelial growth factor (R&D Systems) as previously described. 7
Dual-Luciferase Activity Assay
To confirm Bim (a potent apoptotic activator) as the target gene of our miRNA prosurvival cocktail, the 3ЈUTR segments of mouse Bim were inserted into the downstream of firefly luciferase in the pGL3 control vector. The luciferase reporters, pRL-TK control vector plus miRNA oligo precursors (Applied Biosystems), were transfected into National Institutes of Health 3T3 cells by Lipofectamine 2000 (Invitrogen) in Opti-MEM. Cell lysates were harvested in 24 hours after transfection. Firefly and renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega) as previously described. 19 
Intramuscular Injection of CPCs for Assessment of the MiRNA Cocktail
To compare the survival between CPCs treated with the miRNA prosurvival cocktail and CPCs alone, we injected the 2 cell types into the legs of the same animal. This method allowed us to avoid interindividual variation and perform an unbiased head-to-head comparison. We injected 5ϫ10 5 cells into the hind limb of adult female SCID/Beige mice (Charles River Laboratories, Wilmington, MA) with a total volume of 10 L per injection leg (nϭ8 animals).
Surgical Model of Murine Myocardial Infarction and Cell Delivery
All animal research protocols were approved by the Stanford Animal Research Committee. Ligation of the midleft anterior descending artery was performed in adult female SCID Beige mice (Charles River Laboratories) by a single experienced microsurgeon (Y.G.). MI was confirmed by myocardial blanching and electrocardiographic changes. Mice (14 weeks old) were randomized into 3 groups (nϭ60 total): (1) phosphate-buffered saline (PBS); (2) 2ϫ10 6 CPCs alone; and (3) 2ϫ10 6 CPCs transduced with the 3 miRNA cocktail (nϭ20/group). After left anterior descending artery ligation, the animals were injected with CPCs or PBS in the peri-infarct zone at 2 different sites with total volume of 30 L using a 31-gauge Hamilton syringe.
In Vivo Optical Bioluminescence Imaging
See Supplemental Methods (http://circ.ahajournals.org).
Echocardiographic Analysis of Left Ventricular Function
See Supplemental Methods.
Histological Examination
Statistical Analysis
Statistics were calculated using SPSS 12.0 (SPSS Inc, Chicago, IL). Descriptive statistics included mean and SD. One-way analysis of variance and 2-way repeated-measures analysis of variance with post hoc testing were used. The initial F test was followed up with the Bonferroni multiple comparisons procedure. Differences were considered significant at probability values of Ͻ0.05.
Results
Characterization and Differentiation of CPCs
After purification by anti-Sca-1 microbeads, the typical CPCs showed high nucleus-to-cytoplasm ratios. The adherent cells sprouted new round bright cells at their cell body ( Figure 1A ). Fluorescence-activated cell sorting indicated that isolated CPCs were Ͼ95% Sca-1 ϩ and CD45 Ϫ ; the latter is a marker for hematopoietic stem cells ( Figure 1B ). The isolated CPCs expressed robust levels of Fluc and green fluorescent protein ( Figure 1C-D) . Next, we differentiated CPCs using induction medium. After 7 days of differentiation into cardiomyocytes and smooth muscle cells, the differentiated cells stained positive for connexin 43 ( Figure 1E ), cardiac troponin T ( Figure 1F ), myocyte-specific enhancer factor 2C ( Figure  1G ), and ␣-smooth muscle actin ( Figure 1H ). Furthermore, CPCs could be differentiated into endothelial cells ( Figure  1I ). The differentiated endothelial cells demonstrated DiI-ac-LDL uptake ( Figure 1J ) and could form tube-like structures on Matrigel angiogenesis assay ( Figure 1K ). In contrast, the undifferentiated CPCs were not able to form similar tube-like structures ( Figure 1L ).
Screening of MiRNA Candidates for Improving CPC Survival
To identify potential prosurvival miRNAs in CPCs, we tested the cell viability after serum-free challenge. We tested several miRNAs or miRNA clusters, including miR-21, miR24, miR-210, miR-221, miR-17-92, and miR106b-25, which have been shown to improve cell survival or inhibit cell apoptosis in previous studies. 17,20 -23 After transduction with individual miRNA, miRNA cluster, or control lentivirus, CPCs were challenged in serum-free condition for 24 hours. Cell viability was used as a criterion to evaluate miRNA capacity to improve cell survival. Overall, we found that CPCs treated individually with miR-21, miR-24, and miR-221 had significantly higher cell viability compared with control CPCs that were transduced with green fluorescent protein ( Figure 2 ). CPCs treated with the 3 miRNA cocktail (miR-21, miR-24, and miR-221) showed the highest cell viability, suggesting synergistic benefits in action.
Comparison of CPC Survival After Intramuscular Transplantation
We first evaluated the correlation between Fluc expression and cell numbers ( Figure 3A) . Our data showed a robust linear correlation (R 2 ϭ0.99) between bioluminescence signals and cell numbers, which is crucial for accurate tracking of cell fate after in vivo imaging studies ( Figure 3B ). Next, we assessed cell viability in vivo of CPCs alone versus CPCs treated with the 3 miRNA cocktail after intramuscular injection by bioluminescence imaging. By injecting the 2 cell types into the same animal, we were able to avoid interindividual variation and perform a head-to-head comparison of cell survival attributed to the 3 miRNA cocktail. Bioluminescence imaging indicated Fluc activity from CPCs treated with miRNA cocktail was stable for at least 14 days after intramuscular injection. In contrast, CPCs alone lost their biolu- Figure 4B ). Overall, these data demonstrated that CPCs treated with the miRNA cocktail could survive longer post-transplantation than CPCs alone in a hind limb model without ischemic injury.
Assessment of CPC Fate and Function After MI
To examine whether the miRNA cocktail can also enhance cell survival in an ischemic injury milieu, mice underwent left anterior descending artery ligation and intramyocardial injection with (1) PBS; (2) CPCs alone; and (3) CPCs treated with the miRNA cocktail. To investigate the systemic cell distribution of CPCs after intramyocardial cell delivery, we harvested the whole heart, liver, spleen, and lung tissues for individual tissue bioluminescence analysis ex vivo. At 72 hours after cell delivery, we found the majority of bioluminescence signal in explanted heart but not in the lung, liver, and spleen (Supplemental Figure I) . In vivo bioluminescence imaging demonstrated significantly stronger Fluc activity in the infarcted hearts of animals injected with CPCs treated with the miRNA cocktail compared with CPCs alone at all time points: Day 3, Day 7, Day 14, Day 21, and Day 28 ( Figure 4C-D) . For functional assessment, the baseline left ventricular fractional shortening was comparable in all 3 groups (Figure 5A-B Figure 5C ). Immunostaining of explanted hearts also confirmed that the population of green fluorescent protein ϩ cells in CPCs treated with the miRNA cocktail is significantly higher than CPC alone and PBS control groups ( Figure 5D ).
Prediction and Confirmation of MiRNA Targets
To elucidate the potential targets of these miRNAs, we predicted the target genes of miR-21, miR-24, and miR-221 using both TargetScan and MicroCosm, which are based on different prediction algorithms. 24 Irrespective of site conservation, 1791 genes were predicted as potential target genes of mouse miR-21, 3048 genes as the potential target genes of mouse miR-24, and 2295 genes as the potential target genes of mouse miR-221. Bioinformatics analysis indicated many apoptotic genes are the targets of these 3 miRNAs, which are putatively suppressed by these miRNAs. These apoptotic genes include Casp3, Casp8ap2, Bax, Pdcd4, and Fasl. Interestingly, 106 genes are predicted as the common targets of all 3 miRNAs. Some of these 106 genes include apoptotic activators or effectors (including Bcl2l11, Foxo3, and Ak2), which are potential suppression targets by all of the 3 miRNAs (Supplemental Figure II) . Bcl2l11, also named Bim, belongs to the Bcl-2 protein family. Interestingly, Bim has shown to be a critical apoptotic activator, which prompted us to perform further experimental analysis. 25 There are a total of 6 binding sites on the 3ЈUTR of Bim, including 1 binding site of miR-21, 2 binding sites of miR-24, and 3 binding sites of miR-221 ( Figure 6A ; Supplemental Figure III ). To experimentally validate this bioinformatic prediction, we used the luciferase reporter assay. The 6 miRNAs binding segments of 3ЈUTR of Bim were amplified by polymerase chain reaction and inserted into downstream of the luciferase reporter gene separately in the pGL3 control vector for the dual-luciferase assay, including 21, 24_1, 24_2, 221_1, 221_2, and 221_3 recombinant reporter ( Figure 6B ). For reporters 21, 24_1, 24_2, 221_2, and 221_3, compared with the precursor miRNA control, their luciferase activity was significantly suppressed by their relative miRNAs. Furthermore, the luciferase activity could not be suppressed by using mismatched miRNAs. For example, luciferase activity of reporter 21 could be suppressed by miR-21, but not by miR-24. However, for reporter 221_1, the luciferase activity was not suppressed by miR-221, indicating that this binding site is dispensable for Bim suppression by miR-221.
Next, we assessed whether miRNAs could regulate Bim expression endogenously. CPCs were transduced with these 3 miRNAs to evaluate whether miRNAs could regulate Bim expression by Western blotting ( Figure 6C ). Compared with control, the levels of Bim isoforms proteins were significantly downregulated by miRNA cocktails. Collectively, these data suggest that Bim is a real target of these miRNA cocktails, as confirmed by bioinformatic prediction and experimental validation. To further elucidate the downstream target of miRNA cocktail treatment, the transduced CPCs were exposed to a serum-free condition and the activated caspase 3 protein levels were evaluated by the Western blotting method. Compared with the control, the protein levels of active caspase 3 were downregulated by miRNA cocktails ( Figure 6D ).
Discussion
MI is the leading cause of morbidity and mortality in the Western world. MI leads to thinning of the infarct wall, cardiac dilatation, and adverse cardiac remodeling. At the cellular level, MI causes cellular apoptosis, necrosis, and fibrosis. Stem cell therapy, which is designed to replenish the infarct area with new cells, is therefore a promising therapeutic strategy. Cardiac progenitor cells, which can be committed to cardiomyocytes, smooth muscle cells, and endothelial cell lineages, are 1 of many potential candidate cell types for cardiovascular regenerative medicine. Although several studies have demonstrated improvement in cardiac function after CPC transplantation, 26, 27 the low survival of the transplanted cells is believed to be one of the main hurdles for the failure to show long-term improvements after cell therapy. 7 MiRNAs are a class of small noncoding RNAs, mainly functioning as negative regulators of protein coding genes. In this study, we report that a novel miRNA prosurvival cocktail can improve the engraftment of the transplanted CPCs. Consequently, the longer surviving CPCs could lead to better functional recovery. We first isolated CPCs from transgenic mice that constitutively express Fluc and green fluorescent protein. These isolated CPCs can differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells under proper induction protocols. 7, 28 Afterward, we selected several miRNA candidates that have been shown to improve cell survival or inhibit cell apoptosis. Cell viability analysis demonstrated that miR-21, miR-24, and miR-211 were particularly potent compared with control. Furthermore, when transduced with these 3 miRNAs as a cocktail, we found that CPCs had significantly better cell viability both in vitro and in vivo, which led to improved function as demonstrated by echocardiography and histology.
MiR-21 displays strong evolutionary conservation across a wide range of species and is expressed in mammalian organ systems such as the heart, spleen, small intestine, and colon. 29 MiR-21 is overexpressed in many tumor samples with antiapoptotic roles by inhibiting several apoptotic genes. Most recently, miR-21 has been found to play important roles in cardiovascular biology in the areas of vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. 30 Overexpression of miR-21 can significantly decrease infarct size in mouse acute MI models by targeting PDCD4 and its downstream molecule AP1. 31 In addition, miR-21 has a predominant effect on cardiac fibroblasts in response to ischemia/reperfusion in the mouse heart by suppression of PTEN. 32 MiR-24 also has been shown to be an antiapoptotic miRNA in the developing neural retina 22 and tumorigenesis. 33 miR-221 is involved as a miRNA in several cancer cells by functioning as an antiapoptotic regulator by suppressing PTEN. 34 Antisense inhibition of miR-21 or miR-221 can arrest cell cycle and induce apoptosis in pancreatic adenocarcinoma. 21 To elucidate the molecular mechanism of CPC survival by the miRNA prosurvival cocktail, we performed target prediction of these 3 miRNAs. We found these miRNAs potentially suppress many classic apoptotic genes, including Casp3, Casp8ap2, Bax, Pdcd4, and Fasl as well as Bim, Foxo3, and Ak2, which can be inhibited by all the 3 miRNAs. Bim is of particular interest because it belongs to the Bcl-2 protein family and can interact with other members of the family, including Bcl2, Bcl-xL, and Mcl-1. 25 Bim mainly functions as a critical apoptotic activator. Bim gives rise to a variety of isoforms, including the most extensively studied cytotoxic splice variants, Bim s , Bim L, and Bim EL . 25 Overexpression of Bim in cardiac myocytes can induce apoptosis. 35 Our dual-luciferase assay indicated that all 3 miRNAs can bind to the 3ЈUTR of Bim transcript and suppress its expression. Bim has been shown to activate caspase cascades by inducing cytochrome c release from mitochondria and induce apoptosis of cells. 13, 36, 37 Furthermore, Western blotting indicated that the miRNA cocktail inhibits Bim and subsequently suppresses activation of caspase 3, contributing to the survival of CPCs. Our data demonstrated that miR-21, miR-24, and miR-221 can inhibit the apoptotic Bim and can improve cell survival after challenge with serum-free stress in vitro and ischemic stress in vivo. Taken together, we believe the inhibition of potent proapoptotic Bim by the miRNA cocktail presents a novel and an important avenue for promoting cell survival.
Several cell types have been used for clinical trials. 37, 38 However, there is still little convincing evidence that stem cells can engraft significantly in the myocardium. 6 It is thought that massive cell death after transplantation may be a major limiting factor that impedes long-term cardiac recovery. Therefore, developing prosurvival or antiapoptosis strategies to boost stem cell survival after transplantation may benefit this field. Cellular preconditioning by physical, chemical, genetic, and pharmacological manipulation has shown that the cells can better with- stand the rigors of lethal ischemia in vitro as well as posttransplantation. 39 We report that a novel miRNA prosurvival cocktail (miR-21, miR-24, and miR221) can also significantly improve CPC engraftment through suppression of proapoptotic Bim. Transplantation of CPCs treated with the miRNA cocktail can lead to significant improvement in cardiac function in a murine MI model. Hence, miRNAs may provide a valuable method to promote cell survival by regulating multiple target genes or even an entire gene network.
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